All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, What are the new clinical advances in MDS risk categorization?
New clinical advances in MDS risk categorization
In this video, de Witte discusses the current landscape of diagnosis and prognosis for patients with MDS, alongside the current drugs available, including lenalidomide and hypomethylating agents (HMAs). He also highlights how mutations and variant allele frequency (VAF) can affect patient outcome.
EHA2021 practice-changing abstracts in myelodysplastic syndromes
World-leading experts in MDS shared the top abstracts from the EHA2021 Virtual Congress that they believed could have the greatest impact on clinical practice.
Practice-changing abstracts at EHA 2020
The MDS Hub was pleased to speak to Steering Committee Chair Theo De Witte, Radboudumc, Nijmegen, NL, about practice-changing abstracts from the 25th European Hematology Association (EHA) Annual Congress.
Subscribe to get the best content related to MDS delivered to your inbox